Dr.RenalNash said:Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…
That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.
anders_CPH said:ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…
This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.
Dr.RenalNash said:Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…
This is where I part company with the consensus forming above. Pushing back on the consensus forming here. Consistency is not the same as correctness, and a board that agrees with itself quickly is usually agreeing with the first person who sounded certain.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsAdding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.
Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again.